Sign in
ABEO Stock Price, Chart, Stats & News
Abeona Therapeutics Inc.
Save
Abeona Therapeutics Inc. (ABEO) does not currently pay a dividend.
372.18M
Market cap
6.73x
Current P/E
526.32x
Forward P/E
ABEO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 26.32% |
Operating margin | -1536.91% |
Pretax margin | 1224.79% |
Net margin | 1223.08% |
Effective tax rate | 0.14% |
ROA | 32.42% |
ROE | 53.18% |
D/E | 0.16x |
Interest coverage ratio | -23.92x |
ABEO valuation
P/E | 6.73x |
P/S | 42.05x |
P/B | 1.43x |
P/CF | -2.98x |
P/FCF | -2.90x |
P/OCF | -2.98x |
PEG | -0.30x |
EV multiple | -3.47x |
About
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A.
Similar securities
Based on sector and market capitalization
Report issue